Intel 10-Q 2025-09-27
INTC · CIK 50863 · Form 10-Q · Period ended September 27, 2025 · Filed November 6, 2025
Revenue rose 2.8% to $13.7 billion. Operating margin was 5.0%, against -68.2% a year earlier. Net income was $4.06 billion.
8 sections, 289K characters. Original on sec.gov · ·
| Measure | Quarter ended Sep 27, 2025 | Quarter ended Sep 28, 2024 | Change |
|---|---|---|---|
| Revenue | $13.7B | $13.3B | +2.8% |
| Operating income | $683M | -$9.06B | n/a |
| Net income | $4.06B | -$16.6B | n/a |
| Diluted EPS | $0.90 | -$3.88 | n/a |
| Cash and equivalents | $11.1B | n/a | n/a |
| Operating margin* | 5.0% | -68.2% | +73.2 pts |
From the XBRL facts tagged to this filing; both columns are as reported in this filing. * Computed by filings.tools: free cash flow is operating cash flow less capital spending; operating margin is operating income over revenue.
Cover and table of contents
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
| ☑ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | ||||||||||
| For the quarterly period ended | September 27, 2025 |
or
| ☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | |||||||
| For the transition period from to |
Commission File Number: 000-06217

INTEL CORPORATION
(Exact name of registrant as specified in its charter)
| Delaware | 94-1672743 | |||||||||||||
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | |||||||||||||
| 2200 Mission College Boulevard, | Santa Clara, | California | 95054-1549 | |||||||||||
| (Address of principal executive offices) | (Zip Code) |
(408) 765-8080
(Registrant’s telephone number, including area code)
N/A
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol(s) | Name of each exchange on which registered | ||||||
| Common stock, $0.001 par value | INTC | Nasdaq Global Select Market |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ¨
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | Accelerated filer | Non-accelerated filer | Smaller reporting company | Emerging growth company | |||||||||||||||||||
| ☑ | ¨ | ¨ | ☐ | ☐ | |||||||||||||||||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☑
As of October 31, 2025, the registrant had outstanding 4,770 million shares of common stock.
Table of Contents
Organization of Our Form 10-Q
The order and presentation of content in our Form 10-Q differs from the traditional SEC Form 10-Q format. Our format is designed to improve readability and better present how we organize and manage our business. See "Form 10-Q Cross-Reference Index" within Risk Factors and Other Key Information for a cross-reference index to the traditional SEC Form 10-Q format.
We have defined certain terms and abbreviations used throughout our Form 10-Q in "Key Terms" within the Consolidated Condensed Financial Statements and Supplemental Details.
| Page | |||||||||||
| Forward-Looking Statements | 1 | ||||||||||
| Availability of Company Information | 2 | ||||||||||
| Consolidated Condensed Financial Statements and Supplemental Details | |||||||||||
| Consolidated Condensed Statements of Operations | 3 | ||||||||||
| Consolidated Condensed Statements of Comprehensive Income (Loss) | 4 | ||||||||||
| Consolidated Condensed Balance Sheets | 5 | ||||||||||
| Consolidated Condensed Statements of Cash Flows | 6 | ||||||||||
| Consolidated Condensed Statements of Stockholders' Equity | 7 | ||||||||||
| Notes to Consolidated Condensed Financial Statements | 8 | ||||||||||
| Key Terms | 28 | ||||||||||
| Management's Discussion and Analysis (MD&A) | |||||||||||
| Operating Segments Trends and Results | 32 | ||||||||||
| Consolidated Condensed Results of Operations | 36 | ||||||||||
| Liquidity and Capital Resources | 42 | ||||||||||
| Risk Factors and Other Key Information | |||||||||||
| Risk Factors | 44 | ||||||||||
| Quantitative and Qualitative Disclosures About Market Risk | 45 | ||||||||||
| Controls and Procedures | 45 | ||||||||||
| Issuer Purchases of Equity Securities | 46 | ||||||||||
| Rule 10b5-1 Trading Arrangements | 46 | ||||||||||
| Disclosure Pursuant to Section 13(r) of the Securities Exchange Act of 1934 | 46 | ||||||||||
| Exhibits | 47 | ||||||||||
| Form 10-Q Cross-Reference Index | 48 |
Forward-Looking Statements
This Form 10-Q contains forward-looking statements that involve a number of risks and uncertainties. Words such as "accelerate", "achieve", "aim", "ambitions", "anticipate", "believe", "committed", "continue", "could", "designed", "estimate", "expect", "forecast", "future", "goals", "grow", "guidance", "intend", "likely", "may", "might", "milestones", "next generation", "objective", "on track", "opportunity", "outlook", "pending", "plan", "position", "possible", "potential", "predict", "progress", "ramp", "roadmap", "seek", "should", "strive", "targets", "to be", "upcoming", "will", "would", and variations of such words and similar expressions are intended to identify such forward-looking statements, which may include statements regarding:
**▪**our business plans and strategy and anticipated benefits therefrom;
**▪**projections of our future financial performance, including future revenue, gross profits, capital expenditures, and cash flows;
**▪**projected costs and yield trends;
**▪**future cash requirements, the availability, uses, sufficiency, and cost of capital resources, and sources of funding, including for future capital and R&D investments and for returns to stockholders, such as stock repurchases and dividends, and credit ratings expectations;
**▪**future products, services, and technologies, and the expected goals, timeline, ramps, progress, availability, production, regulation, and benefits of such products, services, and technologies, including future process nodes and packaging technology, product roadmaps, schedules, future product architectures, expectations regarding process performance, per-watt parity, and metrics, and expectations regarding product and process leadership;
**▪**investment plans and impacts of investment plans, including in the U.S. and abroad;
**▪**internal and external manufacturing plans, including future internal manufacturing volumes, manufacturing expansion plans and the financing therefor, and external foundry usage;
**▪**future production capacity and product supply;
**▪**supply expectations, including regarding constraints, limitations, pricing, and industry shortages;
**▪**plans and goals related to Intel's foundry business, including with respect to anticipated customers, future manufacturing capacity and service, technology, and IP offerings;
**▪**expected timing and impact of acquisitions, divestitures, and other significant transactions;
**▪**expected completion and impacts of restructuring activities and cost-saving or efficiency initiatives;
**▪**future social and environmental performance goals, measures, strategies, and results;
**▪**our anticipated growth, future market share, customer demand, and trends in our businesses and operations;
**▪**projected growth and trends in markets relevant to our businesses;
**▪**anticipated trends and impacts related to industry component, substrate, and foundry capacity utilization, shortages, and constraints;
**▪**expectations regarding government funding, incentives, policies, and priorities;
**▪**future technology trends and developments, such as AI;
**▪**future macro environmental and economic conditions;
**▪**geopolitical tensions and conflicts, including with respect to international trade policies in areas such as tariffs and export controls, and their potential impact on our business;
**▪**tax- and accounting-related expectations;
**▪**expectations regarding our relationships with certain sanctioned parties; and
**▪**other characterizations of future events or circumstances.
Such statements involve many risks and uncertainties that could cause our actual results to differ materially from those expressed or implied, including those associated with:
**▪**the high level of competition and rapid technological change in our industry;
**▪**the significant long-term and inherently risky investments we are making in R&D and manufacturing facilities that may not realize a favorable return;
**▪**the complexities and uncertainties in developing and implementing new semiconductor products and manufacturing process technologies;
**▪**our ability to time and scale our capital investments appropriately and successfully secure favorable alternative financing arrangements and government grants;
**▪**a potential pause or discontinuation of our pursuit of Intel 14A and other next generation leading-edge process technologies if we are unable to secure a significant external customer for Intel 14A;
**▪**implementing new business strategies and investing in new businesses and technologies;
**▪**changes in demand for our products;
**▪**macroeconomic conditions and geopolitical tensions and conflicts, including geopolitical and trade tensions between the U.S. and China, the impacts of Russia's war on Ukraine, tensions and conflict affecting Israel and the Middle East, and rising tensions between mainland China and Taiwan;
| 1 |
**▪**the evolving market for products with AI capabilities;
**▪**our complex global supply chain supporting our manufacturing facilities and incorporating external foundries, including from disruptions, delays, trade tensions and conflicts, or shortages;
**▪**recently elevated geopolitical tensions, volatility and uncertainty with respect to international trade policies, including tariffs and export controls, impacting our business, the markets in which we compete and the world economy;
**▪**product defects, errata and other product issues, particularly as we develop next-generation products and implement next-generation manufacturing process technologies;
**▪**potential security vulnerabilities in our products;
**▪**increasing and evolving cybersecurity threats and privacy risks;
**▪**IP risks including related litigation and regulatory proceedings;
**▪**the need to attract, retain, and motivate key talent;
**▪**strategic transactions and investments;
**▪**sales-related risks, including customer concentration and the use of distributors and other third parties;
**▪**our significantly reduced return of capital in recent years;
**▪**U.S. government ownership of significant equity interests in the company;
**▪**our debt obligations and our ability to access sources of capital;
**▪**complex and evolving laws and regulations across many jurisdictions;
**▪**fluctuations in currency exchange rates;
**▪**changes in our effective tax rate and applicable tax regimes;
**▪**catastrophic events;
**▪**environmental, health, safety, and product regulations;
**▪**our initiatives and new legal requirements with respect to corporate responsibility matters; and
**▪**other risks and uncertainties described in this report, our 2024 Form 10-K, our Q1 2025 Form 10-Q, our Q2 2025 Form 10-Q and our other filings with the SEC.
Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Readers are urged to carefully review and consider the various disclosures made in this Form 10-Q and in other documents we file from time to time with the SEC that disclose risks and uncertainties that may affect our business.
Unless specifically indicated otherwise, the forward-looking statements in this Form 10-Q do not reflect the potential impact of any divestitures, mergers, acquisitions, or other business combinations that have not been completed as of the date of this filing. In addition, the forward-looking statements in this Form 10-Q are based on management's expectations as of the date of this filing, unless an earlier date is specified, including expectations based on third-party information and projections that management believes to be reputable. We do not undertake, and expressly disclaim any duty, to update such statements, whether as a result of new information, new developments, or otherwise, except to the extent that disclosure may be required by law.
Availability of Company Information
We use our Investor Relations website, www.intc.com*,* as a routine channel for distribution of important, and often material, information about us, including our quarterly and annual earnings results and presentations, press releases, announcements, information about upcoming webcasts, analyst presentations, and investor days, archives of these events, financial information, corporate governance practices, and corporate responsibility information. We also post our filings on this website the same day they are electronically filed with, or furnished to, the SEC, including our annual and quarterly reports on Forms 10-K and 10-Q and current reports on Form 8-K, our proxy statements, and any amendments to those reports. All such information is available free of charge. Our Investor Relations website allows interested persons to sign up to automatically receive e-mail alerts when we post financial information and issue press releases, and to receive information about upcoming events. We encourage interested persons to follow our Investor Relations website in addition to our filings with the SEC to receive timely information about the company.
Intel, the Intel logo, Intel Core, Gaudi, and Altera are trademarks of Intel Corporation or its subsidiaries in the U.S. and/or other countries.
** Other names and brands may be claimed as the property of others.*
| 2 |
Item 1. Financial Statements
| Consolidated Condensed Statements of Operations | |||||
| Three Months Ended | Nine Months Ended | |||||||||||||||||||||||||
| (In Millions, Except Per Share Amounts; Unaudited) | Sep 27, 2025 | Sep 28, 2024 | Sep 27, 2025 | Sep 28, 2024 | ||||||||||||||||||||||
| Net revenue | $ | 13,653 | $ | 13,284 | $ | 39,179 | $ | 38,841 | ||||||||||||||||||
| Cost of sales | 8,435 | 11,287 | 25,747 | 27,080 | ||||||||||||||||||||||
| Gross profit | 5,218 | 1,997 | 13,432 | 11,761 | ||||||||||||||||||||||
| Research and development | 3,231 | 4,049 | 10,555 | 12,670 | ||||||||||||||||||||||
| Marketing, general, and administrative | 1,129 | 1,383 | 3,450 | 4,268 | ||||||||||||||||||||||
| Restructuring and other charges | 175 | 5,622 | 2,221 | 6,913 | ||||||||||||||||||||||
| Operating expenses | 4,535 | 11,054 | 16,226 | 23,851 | ||||||||||||||||||||||
| Operating income (loss) | 683 | (9,057) | (2,794) | (12,090) | ||||||||||||||||||||||
| Gains (losses) on equity investments, net | 221 | (159) | 611 | (74) | ||||||||||||||||||||||
| Interest and other, net | 3,670 | 130 | 3,402 | 355 | ||||||||||||||||||||||
| Income (loss) before taxes | 4,574 | (9,086) | 1,219 | (11,809) | ||||||||||||||||||||||
| Provision for (benefit from) taxes | 304 | 7,903 | 860 | 7,271 | ||||||||||||||||||||||
| Net income (loss) | 4,270 | (16,989) | 359 | (19,080) | ||||||||||||||||||||||
| Less: net income (loss) attributable to non-controlling interests | 207 | (350) | 35 | (450) | ||||||||||||||||||||||
| Net income (loss) attributable to Intel | $ | 4,063 | $ | (16,639) | $ | 324 | $ | (18,630) | ||||||||||||||||||
| Earnings (loss) per share attributable to Intel—basic | $ | 0.90 | $ | (3.88) | $ | 0.07 | $ | (4.37) | ||||||||||||||||||
| Earnings (loss) per share attributable to Intel—diluted****¹ | $ | 0.90 | $ | (3.88) | $ | 0.07 | $ | (4.37) | ||||||||||||||||||
| Weighted average shares of common stock outstanding: | ||||||||||||||||||||||||||
| Basic | 4,514 | 4,292 | 4,424 | 4,267 | ||||||||||||||||||||||
| Diluted | 4,531 | 4,292 | 4,434 | 4,267 |
1 For the three and nine months ended September 27, 2025, earnings (loss) per share attributable to Intel-diluted has been calculated by adjusting net income (loss) attributable to Intel for the loss of $2 million related to the mark-to-market of that portion of the derivative liability that is attributable to 342 thousand contingent Escrowed Shares that were included in the weighted average shares of common stock outstanding-diluted during the period.
See accompanying notes.
![]() | Financial Statements | Consolidated Condensed Statements of Operations | 3 |
| Consolidated Condensed Statements of Comprehensive Income (Loss) | |||||
| Three Months Ended | Nine Months Ended | |||||||||||||||||||||||||
| (In Millions; Unaudited) | Sep 27, 2025 | Sep 28, 2024 | Sep 27, 2025 | Sep 28, 2024 | ||||||||||||||||||||||
| Net income (loss) | $ | 4,270 | $ | (16,989) | $ | 359 | $ | (19,080) | ||||||||||||||||||
| Changes in other comprehensive income (loss), net of tax: | ||||||||||||||||||||||||||
| Net unrealized holding gains (losses) on derivatives | (48) | 512 | 727 | 32 | ||||||||||||||||||||||
| Actuarial valuation and other pension benefits (expenses), net | 1 | — | 2 | — | ||||||||||||||||||||||
| Translation adjustments and other | 1 | (1) | 1 | (2) | ||||||||||||||||||||||
| Other comprehensive income (loss) | (46) | 511 | 730 | 30 | ||||||||||||||||||||||
| Total comprehensive income (loss) | 4,224 | (16,478) | 1,089 | (19,050) | ||||||||||||||||||||||
| Less: comprehensive income (loss) attributable to non-controlling interests | 207 | (350) | 35 | (450) | ||||||||||||||||||||||
| Total comprehensive income (loss) attributable to Intel | $ | 4,017 | $ | (16,128) | $ | 1,054 | $ | (18,600) | ||||||||||||||||||
See accompanying notes.
![]() | Financial Statements | Consolidated Condensed Statements of Comprehensive Income (Loss) | 4 |
| Consolidated Condensed Balance Sheets | |||||
| (In Millions; Unaudited) | Sep 27, 2025 | Dec 28, 2024 | ||||||||||||
| *Assets |
Showing the first 8K of 167K characters. Open the full section
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
| Management's Discussion and Analysis | |||||
This report should be read in conjunction with our 2024 Form 10-K where we include additional information on our business, operating segments, risk factors, critical accounting estimates, policies, and the methods and assumptions used in our estimates, among other important information. The Critical Accounting Estimates discussed in our Q2 2025 Form 10-Q , supplement the significant accounting policies outlined in "Note 2: Accounting Policies" within Notes to Consolidated Financial Statements within our 2024 Form 10-K .
In addition, as described under U.S. Government Agreements below in this MD&A and further supplemented within Risk Factors and Other Key Information included elsewhere in this document, we entered into transactions with the U.S. government in Q3 2025 for which the accounting is complex and for which we voluntarily initiated an accounting consultation with the staff of the SEC. Due to the current U.S. government shutdown, we have been unable to conclude our consultation with the staff of the SEC as of the date of this Q3 2025 Form 10-Q filing.
Altera Divestiture
On September 12, 2025, we completed the divestiture of 51% of Altera for net purchase consideration of $4.3 billion, consisting of: $4.3 billion in cash proceeds received at the closing, subject to working capital adjustments and other adjustments under the terms of the transaction agreement, separation agreement, and certain ancillary agreements attached to the transaction; $500 million in deferred cash proceeds also received within the third quarter of 2025; $500 million in deferred cash proceeds payable to us no later than December 31, 2027; an offset of $400 million for cash transferred to Altera with the sale; an offset of approximately $469 million in separation and employee-related costs we have agreed to fund to the purchaser; and an offset for other direct and incremental costs incurred in connection with the sale.
Upon closing the transaction, we deconsolidated Altera from our consolidated financial statements and retained a 49% minority investment in Altera which is accounted for under the equity method of accounting. The $3.2 billion value of our non-marketable equity method investment in Altera is classified within equity investments in the Consolidated Condensed Balance Sheets at September 27, 2025. The Altera divestiture resulted in a pre-tax gain of $5.5 billion recognized within interest and other, net, which is net of certain costs we have agreed to fund to SLP, as well as direct and incremental costs we incurred to sell the business. Refer to "Note 9: Divestitures" within Notes to Consolidated Condensed Financial Statements for further information.
U.S. Government Agreements
On August 22, 2025, we entered into a Warrant and Common Stock Agreement (U.S. Government Agreement) with the U.S. Department of Commerce's (DOC) to support the continued expansion of American semiconductor technology and manufacturing leadership. On August 27, 2025, pursuant to the terms of the U.S. Government Agreement:
▪we entered into an amendment to our commercial CHIPs Act agreement with the DOC removing the prior project milestone requirements and other conditions to disbursements under the agreement, as well as substantially all other requirements under the agreement other than those required by law, including those associated with the $2.3 billion previously received and recognized by us as government incentives pursuant to our government grant accounting policy;
▪we received the full amount of the accelerated disbursements remaining under the commercial CHIPs Act agreement of $5.7 billion;
▪we issued to the DOC 275 million shares of our common stock and a warrant to purchase up to 241 million shares of our common stock at $20.00 per share if we were to cease to directly or indirectly own at least 51% of our foundry business; and
▪we issued into escrow 159 million shares of our common stock, to be released to the U.S. government on a $20.00 per share basis as we receive the $3.2 billion of disbursements contemplated by our existing agreement and related performance obligations with the U.S. government under the CHIPs Act's Secure Enclave program (684 thousand shares were subsequently released upon receipt of disbursements during Q3 2025).
Refer to “Note 4: Earnings (Loss) Per Share and Stockholders' Equity" within Notes to Consolidated Condensed Financial Statements and "Risk Factors" within Risk Factors and Other Key Information for additional details.
Private Placement Share Sale Agreements
In Q3 2025, we entered into two agreements for the issuance and sale of shares of our common stock in private placements to support our strategic investments in advanced manufacturing, AI infrastructure, and long-term growth initiatives:
▪on August 18, 2025, we entered into an agreement with SoftBank Group to issue and sell to SoftBank Group 87 million shares of our common stock at $23.00 per share, representing an aggregate cash purchase price of $2.0 billion. The issuance and sale of the shares was completed on September 26, 2025; and
▪on September 15, 2025, we entered into an agreement with NVIDIA to issue and sell to NVIDIA 215 million shares of our common stock at $23.28 per share for an aggregate cash purchase price of $5.0 billion. The closing of the issuance and sale, which represents a standalone transaction, remains subject to customary closing conditions.
![]() | MD&A | 29 |
Restructuring Actions and Other Charges
2025
In Q2 2025, we initiated an enterprise-wide initiative to fundamentally transform our culture and the way in which we operate, which is designed to simplify the way we do business and drive transparency and accountability across the company. As part of this transformation, we implemented the 2025 Restructuring Plan to lower expenses, streamline our organizational structure and reduce management layers across functions while reallocating resources toward our core client and server businesses by reducing investment in lower-priority programs and initiatives. We expect these headcount reduction initiatives will reduce our core Intel workforce by approximately 15% by the end of fiscal 2025, as compared to our Q2 2025 ending employee headcount. In YTD 2025, we recognized restructuring charges of $2.2 billion, consisting primarily of charges from our initiating and deploying the 2025 Restructuring Plan and including some remaining charges as we substantially completed the 2024 Restructuring Plan. Charges in YTD 2025 were primarily composed of cash-based employee severance and related employee exit charges of $1.8 billion and non-cash asset impairment charges of $416 million resulting from the exit of certain non-core lines of business and the consolidation and exit of certain real estate properties.
Our YTD 2025 results of operations were also affected by accelerated depreciation and impairment charges recognized for certain manufacturing assets that were determined to have no remaining operational use. This determination was based on an evaluation of our current process technology node capacities relative to projected market demand for our products and services. These non-cash charges of $797 million, net of certain items, were recorded to cost of sales in Q2 2025, impacting the results for our Intel Foundry segment.
2024
The quarter-over-quarter and year-over-year comparisons in this discussion and analysis are, in many instances, materially impacted
Showing the first 8K of 76K characters. Open the full section
Item 1A. Risk Factors
Risk Factors
The risks described in "Risk Factors" within Risk Factors and Other Key Information in our 2024 Form 10-K, our Q1 2025 Form 10-Q and our Q2 2025 Form 10-Q could materially and adversely affect our business, financial condition, and results of operations, and the trading price of our common stock could decline. These risk factors do not identify all risks that we face—our operations could also be affected by factors that are not presently known to us or that we currently consider to be immaterial to our operations. Due to risks and uncertainties, known and unknown, our past financial results may not be a reliable indicator of future performance and historical trends should not be used to anticipate results or trends in future periods. In addition to the other information set forth in this Form 10-Q, including in the Forward-Looking Statements, MD&A, and the Consolidated Condensed Financial Statements and Supplemental Details sections, we have provided additional risk factors below.
There is limited precedent for the accounting treatment for our transactions with the U.S. government and we have been unable to conclude our consultation with the staff of the SEC; if the staff of the SEC were to have a different view of the appropriate accounting treatment, we may materially revise our third quarter financial results, including the recognition of additional costs or losses, and our results for future periods may also be materially and adversely impacted.
Our transactions with the U.S. government during the third quarter of 2025, including the equity issuances and the amendment to our commercial CHIPs Act agreement, are complex. Refer to "Note 4: Earnings (Loss) Per Share and Stockholders' Equity" within Notes to Consolidated Condensed Financial Statements for additional information. There is limited precedent for the accounting treatment of such transactions. While we believe we have selected the appropriate accounting approach for these transactions in our Consolidated Condensed Financial Statements in this Form 10-Q, there are other potential approaches that, if applied, would result in materially different financial results for our third quarter of 2025 and could also materially and adversely impact our results for future periods. Given the complexity associated with these transactions, we recently initiated a consultation with the staff of the SEC to seek confirmation that they do not disagree with our accounting treatment. Due to the current U.S. government shutdown, we have been unable to conclude our consultation with the staff of the SEC. If the staff of the SEC were to have a different view of the appropriate accounting treatment of these transactions, we may materially revise our third quarter 2025 financial results, including the recognition of additional costs or losses, and our results for future periods may also be materially and adversely impacted.
The U.S. government’s acquisition and ownership of significant equity interests in the company may subject us and our stockholders to a number of risks and uncertainties, any of which could have a material adverse effect on our business, financial condition and results of operations or adversely impact the interests of our other stockholders.
■The accelerated CHIPs Act funds we received from the U.S. government connected to the issuance of our equity securities to the U.S. government may be subject to risks from changes in laws, regulations, or their interpretations, as well as shifts in federal administration and congressional priorities. The legislative, judicial or executive branches of the U.S. government could determine in the future that all or a portion of the transactions pursuant to which the U.S. government acquired our equity securities were unauthorized, void or voidable. In addition, the terms of our agreement with the U.S. Department of Commerce for the acquisition of our securities and the amendment of our commercial CHIPs Act agreement are subject to unilateral amendment by the U.S. Department of Commerce to comply with future changes in federal law. Further, while the U.S. Department of Commerce is contractually bound under our agreements with them, no other agency or branch of the U.S. government has made commitments to support, refrain from challenging or otherwise impeding the transaction. Legal challenges, administrative rulings, litigation by other parts of the U.S. government or third parties, or geopolitical developments could materially impair funding, alter obligations under the commercial CHIPs Act agreement or our Secure Enclave agreement, or otherwise adversely affect the transactions and the benefits that we expect to receive under such agreements. In addition, enforcement against a government counterparty is inherently uncertain given the defenses available to the U.S. government.
■The transactions eliminate our contractual rights to receive future funds under the commercial CHIPs Act agreement in the form of a grant and may limit our ability to secure grants from government entities in the future. By eliminating future grant funding under the commercial CHIPs Act agreement, the transactions make it such that our business will no longer benefit from the reduced future operating costs made possible by such grant funding. In addition, our business is highly capital intensive and we have a number of other current grant arrangements with government entities, and may seek to pursue such arrangements in the future. It is uncertain whether the transactions may cause other government entities to seek to convert their existing grant arrangements with us into equity or be unwilling to support us with future grants, either of which could limit our access to capital, increase our cost of capital, or increase our future operating costs.
■The transactions are dilutive to existing stockholders. The issuance of shares of common stock to the U.S. government is dilutive to existing stockholders, and stockholders may suffer significant additional dilution if the conditions to the warrants received by the U.S. government are triggered and the warrants are exercised.
■The U.S. government’s equity position in our common stock reduces the voting and other governance rights of our other stockholders and may limit potential future transactions that may be beneficial to our stockholders. As a result of the transactions, the U.S. government is one of our largest stockholders (5.8% as of September 27, 2025) and may acquire additional shares of our common stock as shares are released from escrow to the U.S. government as we perform under and receive disbursements for Secure Enclave (up to an additional 3.2%) or if the conditions to the warrants are triggered (we no
![]() | Other Key Information | 44 |
longer control 51% of our foundry business within the next five years) and the warrants are exercised (up to an additional 4.8%). The U.S. government’s interests may not be the same as those of other stockholders. The U.S. government has agreed to vote its shares of common stock as recommended by our board of directors, subject to applicable law and exceptions to protect the U.S. government’s interests. This reduces the voting influence of other stockholders with respect to the selection of our directors and proposals voted on by stockholders. The existence of the significant U.S. government equity interest in us, the voting of the U.S. government's shares either as directed by our board of directors or the U.S. government, and the U.S. government’s substantial additional powers with respect to the laws and regulations impacting our business, may substantially limit our ability to pursue potential future strategic transactions that may be beneficial to stockholders, including by potentially limiting the willingness of other third parties to engage in such potential strategic transactions with us.
■Our non-U.S. business may be adversely impacted by the U.S. government being a significant stockholder. Sales outside the U.S. accounted for 76% of our revenue for the fiscal year ended December 28, 2024. Having the U.S. government as a significant stockholder could subject us to additional regulations, obligations or restrictions, such as foreign subsidy laws or otherwise, in other countries.
■We may experience other adverse consequences resulting from the announcement or completion of the transactions. There is limited precedent for a U.S. company such as us having the U.S. government take a position as a significant stockholder. As such, it is difficult to foresee all the potential consequences. Among other things, there could be adverse reactions, immediately or over time, from investors, employees, customers, suppliers, other business or commercial partners, foreign governments or competitors. There may also be litigation related to the transaction or otherwise and increased public or political scrutiny with respect to us.
Any of the foregoing could have a material adverse effect on our revenue, operations, financial position, cash flows, access to financing, cost structure, competitiveness, reputation, profitability, and prospects and could exacerbate other risks discussed in our 2024 Form 10-K, Q1 2025 Form 10-Q and Q2 2025 Form 10-Q.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk
We are affected by changes in currency exchange and interest rates, as well as equity and commodity prices. Our risk management programs are designed to reduce, but may not entirely eliminate, the impacts of these risks. We performed an evaluation of these risks to our financial positions as of December 28, 2024, and updated that analysis as of September 27, 2025, to determine whether material changes in market risks pertaining to currency and interest rates or equity and commodity prices have occurred as a result of the changes in international trade policies, including tariffs and export controls. No material revisions were noted since disclosing "Quantitative and Qualitative Disclosures About Market Risk" within MD&A, in our 2024 Form 10-K. Risks related to changes in international trade policies, including tariffs and export controls, particularly those involving the United States and China are described under "Risk Factors" within Risk Factors and Other Key Information in our 2024 Form 10-K and in our Q1 2025 Form 10-Q.
Item 4. Controls and Procedures
Controls and Procedures
Inherent Limitations on Effectiveness of Controls
Our management, including the principal executive officer and principal financial officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well-designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected.
Evaluation of Disclosure Controls and Procedures
Based on management’s evaluation (with the participation of our principal executive officer and principal financial officer), as of the end of the period covered by this report, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act)), were effective to provide reasonable assurance that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and is accumulated and communicated to management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.
Changes in Internal Control Over Financial Reporting
There were no changes to our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the quarter ended September 27, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
![]() | Other Key Information | 45 |
Issuer Purchases of Equity Securities
We have an ongoing authorization, originally approved by our Board of Directors in 2005 and subsequently amended, to repurchase shares of our common stock in open market or negotiated transactions. No shares were repurchased during the quarter ending September 27, 2025. As of September 27, 2025, we were authorized to repurchase up to $110.0 billion, of which $7.2 billion remained available.
We issue RSUs as part of our equity incentive plans. In our Consolidated Condensed Financial Statements, we treat shares of common stock withheld for tax purposes on behalf of our employees in connection with the vesting of RSUs as common stock repurchases because they reduce the number of shares that would have been issued upon vesting. These withheld shares of common stock are not considered common stock repurchases under our authorized common stock repurchase program.
Item 5. Other Information
Rule 10b5-1 Trading Arrangements
Our directors and officers (as defined in Rule 16a-1 under the Exchange Act) may from time to time enter into plans or other arrangements for the purchase or sale of our shares that are intended to satisfy the affirmative defense conditions of Rule 10b5–1(c) or may represent a non-Rule 10b5-1 trading arrangement under the Exchange Act. During the quarter ended September 27, 2025, no such plans or arrangements were adopted or terminated, including by modification.
Disclosure Pursuant to Section 13(r) of the Securities Exchange Act of 1934
Section 13(r) of the Exchange Act requires an issuer to disclose certain information in its periodic reports if it or any of its affiliates knowingly engaged in certain activities, transactions, or dealings with individuals or entities subject to specific U.S. economic sanctions during the reporting period, even when the activities, transactions, or dealings are conducted in compliance with applicable law. On March 2, 2021, the U.S. Secretary of State designated the Federal Security Service of the Russian Federation (FSB) as a party subject to one such sanction. Though Intel has suspended sales in Russia, there may be a need to file documents or engage with FSB as Intel winds up our local Russian offices. All such dealings are explicitly authorized by General License 1B issued by the U.S. Department of the Treasury’s Office of Foreign Assets Control (OFAC), and there are no gross revenues or net profits directly associated with any such dealings by us with the FSB.
On April 15, 2021, the U.S. Department of the Treasury designated Pozitiv Teknolodzhiz, AO (Positive Technologies), a Russian IT security firm, as a party subject to one of the sanctions specified in Section 13(r). Prior to the designation, we communicated with Positive Technologies regarding its IT security research and coordinated disclosure of security vulnerabilities identified by the firm. Based on a license issued by OFAC, we resumed such communications. There are no gross revenues or net profits directly associated with any such activities. We plan to continue these communications in accordance with the terms and conditions of the OFAC license.
![]() | Other Key Information | 46 |
Item 6. Exhibits
Exhibits
† Management contracts or compensation plans or arrangements in which directors or executive officers are eligible to participate.
![]() | Other Key Information | 47 |
Form 10-Q Cross-Reference Index
| Item Number | Item | |||||||
| Part I - Financial Information | ||||||||
| Item 1. | Financial Statements | Pages 3 - 27 | ||||||
| Item 2. | Management's Discussion and Analysis of Financial Condition and Results of Operations | |||||||
| Liquidity and capital resources | Pages 42 - 43 | |||||||
| Results of operations | Pages 29 - 42 | |||||||
| Critical accounting estimates | Page 29 | |||||||
| Item 3. | Quantitative and Qualitative Disclosures About Market Risk | Page 45 | ||||||
| Item 4. | Controls and Procedures | Page 45 | ||||||
| Part II - Other Information | ||||||||
| Item 1. | Legal Proceedings | Pages 25 - 27 | ||||||
| Item 1A. | Risk Factors | Page 44 | ||||||
| Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | Page 46 | ||||||
| Item 3. | Defaults Upon Senior Securities | Not applicable | ||||||
| Item 4. | Mine Safety Disclosures | Not applicable | ||||||
| Item 5. | Other Information | |||||||
| Rule 10b5-1 Trading Arrangements | Page 46 | |||||||
| Disclosure Pursuant to Section 13(r) of the Securities Exchange Act of 1934 | Page 46 | |||||||
| Item 6. | Exhibits | Page 47 | ||||||
| Signatures | Page 49 |
![]() | Other Key Information | 48 |
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| INTEL CORPORATION (Registrant) | |||||||||||||||||
| Date: | November 6, 2025 | By: | /s/ DAVID ZINSNER | ||||||||||||||
| David Zinsner | |||||||||||||||||
| Executive Vice President, Chief Financial Officer, and Principal Financial Officer | |||||||||||||||||
| Date: | November 6, 2025 | By: | /s/ SCOTT GAWEL | ||||||||||||||
| Scott Gawel | |||||||||||||||||
| Corporate Vice President, Chief Accounting Officer, and Principal Accounting Officer |
![]() | 49 |
